Abstract: The present invention provides prodrugs and methods of use thereof.

Abstract: Disclosed are bifunctional targeted protein autophagy degraders that comprise: 1) a small-molecule targeting a protein of interest; 2) a linker; and 3) a small-molecule recruiter of the autophagy adapter LC3B. These degraders target specific proteins for degradation through the autophagy-lysosomal degradation pathway.

Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.

Abstract: Conjugation of polymers to proteins, including biomedically-relevant PEGylation, is a promising approach to address a central challenge of biologics and biotech: the lack of protein stability in demanding non-native environments. Application of conjugation is hindered by the lack of atomic level understanding of protein-polymerinteractions, preventing design of conjugates with predicted properties. An integrative structural and biophysical approach was used to address this challenge using a polymer-modified carbohydrate recognition domain of human galectin-3 (Gal3C), a lectin essential for cellular adhesion and potential biologic. Modification with PEG and other polymers dramatically increased Gal3C thermal stability and redirected its unfolding pathway through forming a stable intermediate. Distinct polymer properties which increased protein thermal stability were revealed. Structural details of Gal3C-polymer conjugates revealed by NMR pointed to the important role of polymer localization.

Abstract: A conjugate compounds or pharmaceutically acceptable salt thereof, comprises a payload and two or more kinds of cell-interacting molecules. The cell-interacting molecules are ligands capable of specifically binding to a cell surface receptor. A method of treating diseases, comprises delivering a payload to a subject.

Abstract: The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.

Abstract: Provided herein are oligonucleotide-antibody complexes, methods of preparing the complexes, and methods of using the complexes (e.g., treating muscle diseases). In particular, provided are compounds of Formula (I) and various methods for the preparation of the compounds. Also provided are pharmaceutical compositions comprising compounds of Formula (I) and methods of treating muscle disease in a subject by administering a compound or composition described herein.

Abstract: Disclosed herein are peptide-pharmaceutical agent conjugates and methods of treating cancer with the conjugates.

Abstract: Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

Abstract: The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.

Abstract: The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: Composition and methods to prevent, inhibit or treat one or more symptoms of cystic fibrosis are provided.

Abstract: The present invention relates to innovative means of DNA sequence editing involving in-situ cut-and-paste (iCAP) or alternatively cut-and-paste in-situ (CAPi). Thus, in various embodiments described herein, the methods of the invention relate to methods of generating paired-end nucleic acid fragment sharing common linker nucleic acid sequences using a nicking endonuclease, a T7 endonuclease, a restriction enzyme or a transposase, methods of analyzing the nucleotides sequences from the linked-paired-end sequenced fragments and methods of de novo whole genome mapping.

Abstract: Provided herein are Class 2 Type V CRISPR systems comprising CRISPR-Cas polypeptides, (e.g., CasX:gRNA systems comprising CasX polypeptides), guide nucleic acids (gRNA), and optionally donor template nucleic acids, useful in the modification of a PTBP1 gene. The systems are also useful in methods for reprogramming certain eukaryotic cells into functional neurons by the knocking down or knocking out the PTBP1 gene in those cells. Also provided are methods of using such systems in methods of treatment of a subject with a PTBP1-related disease.

Abstract: The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg/mL.

Abstract: A vector comprises a polynucleotide encoding an antibody or antibody fragment for use in a method of treatment of a disease or disorder of the central nervous system (CNS) in a subject, wherein the vector transduces or transfects cells of the blood brain barrier (BBB) and the transduced or transfected BBB cells express the antibody or antibody fragment resulting in delivery of the antibody or antibody fragment into the CNS, preferably into the brain parenchyma.

Abstract: Provided is a system for regulating expression of a gene of interest in a target cell, including a recombinant first RNA molecule with (i) a coding sequence for a translation-suppressor protein and (ii) a first microRNA (miR) recognition element in its 3? UTR, wherein the first miR recognition element recognizes a first miR and binding of a first miR to the first miR recognition element reduces translation of the translation suppressor, and a recombinant second RNA molecule, with (i) a coding sequence for the gene of interest, (ii) a recognition sequence for the translation-suppressor, wherein binding of the translation-suppressor to the recognition sequence for the translation-suppressor reduces translation of the gene of interest, and, optionally, (iii) a second miR recognition element in its 3? UTR, wherein the second miR recognition element recognizes one or more second miR and binding of one or more of the one or more second miR to the second miR recognition element reduces translation of the gene of int

Abstract: MiniVectors and compositions containing MiniVectors that target genes implicated in IPF selected from CDH11, STAT3, STAT6, FoxM1, MDM2, TGF?, SMAD, PDGFA, or TLR4 and/or increase intracellular levels of reduced glutathione, relaxin, and p53, are provided, along with uses in the treatment of idiopathic pulmonary fibrosis.

Abstract: A method for a method of prophylaxis and/or therapy of neurological conditions in a subject in need thereof includes the step of administrating a recombinant AAV vector to the subject. Also disclosed is the use of the a recombinant AAV vector in the manufacture of a medicament of prophylaxis and/or therapy of neurological conditions in a subject in need thereof. The recombinant AAV vector includes: PHP.eB; a sequence for introducing the expression of human M3 muscarinic DREADD receptor coupled to Gq (hM3Dq); and an inhibitory neuron-specific Distal-less homeobox (Dlx) gene enhancer sequence.

Abstract: The present technology relates to compositions and methods for modulating expression of genes which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.

Abstract: This disclosure provides systems, methods, and compositions for site specific genetic engineering comprising the use of CRISPR effectors and trans-splicing. The disclosure also relates to methods of using the systems and compositions for treating diseases as well as diagnostics.

Abstract: Provided herein are recombinant self-complementary adeno-associated virus (scAAV) nucleic acid vectors that comprise a ubiquitous eukaryotic promoter, such as elongation factor 1? (EF1?), chicken beta-actin (CBA), and hybrid chicken beta-actin (CBh), followed by a dominant negative RhoA. Also provided herein are methods of use of said vectors, including intraocular injections (e.g., intracameral injections) to reduce intra-ocular pressure (TOP). Also provided herein are plasmids, recombinant scAAV particles, compositions, formulations, and other methods of use related to such vectors.

Abstract: Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain.

Abstract: Disclosed herein are urushiol-containing epicutaneous patches comprising a support material and a urushiol-containing film on a surface of the support material. A surface of the support material is coated with the urushiol-containing film. Also described herein are test panels comprising urushiol-containing epicutaneous patches of varying urushiol content. The test panels can be employed in methods to assess subject sensitivity to urushiol, to determine a dose-response relationship to varying doses of urushiol, and to assess efficacy of treatments to prevent or inhibit urushiol-induced contact dermatitis in a subject.

Abstract: Some embodiments relate to nanoparticle probes for the detection of disease states in a patient or for tissue engineering. In some embodiments, the nanoparticle probe comprises one or more slip bonds that bind to a cell surface structure. In some embodiments, the binding of the nanoparticle probe is selective. In some embodiments, the nanoparticle probe binds to cells having a certain maximum glycocalyx thickness.

Abstract: Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

Abstract: The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: The present invention is generally directed towards compositions comprising ascorbic acid or ascorbate salt and an imaging agent, and related methods. In some embodiments, the imaging agent comprises pyridaben or a pyridaben analog attached to an imaging moiety.

Abstract: The invention relates to a labeling precursor for nuclear medicine diagnostics and theranostics that has the structure with a first PSMA-specific targeting vector TV1, a second targeting vector TV2 having osteoaffinity, a chelator Chel for complexing a radioisotope, and two or three linkers L1, L2 and L3.

Abstract: A PSMA-targeting conjugate or a pharmaceutically acceptable salt which may be used either for preparing a radiopharmaceutical or, once labeled with a radionuclide, as a radiopharmaceutical. The conjugate is of formula (I): A1-L1-Ch-L2-A2 (I) wherein: Ch is a chelator, L1 and L2, identical or different, are a linker whereas A1 and A2, identical or different, are a urea-based PSMA ligand.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

Abstract: An object surface is substantially cleaned by performing heating disinfection on a thin film at a high temperature in a state not contacting the object surface, and then covering and placing the thin film on the object surface. As another method, the object surface is cleaned by performing high-temperature heating on the object surface in a position retreated from its position of use, and then placing the object surface in the position of use again after cooling.

Abstract: A shoes care device includes a first management device, a second management device, a steam generator, and a controller. Each of the first management device and the second management device may be configured to include an inner cabinet, a connection path, a blowing part, and a dehumidifying part. A supply degree of steam, a dehumidification degree by a dehumidifying part, and a flow degree of air circulated in a connection path can be different between the first management device and the second management device, and as a result, the shoes can be managed under different conditions in the first management device and the second management device.

Abstract: A system and apparatus for sanitizing person use items. The system is comprised essentially of a mechanism for emitting sanitizing electromagnetic radiation within an enclosed compartment. The apparatus may be light-tight such that the radiation is contained within the apparatus. It may be configured to emit a plurality of sanitizing wavelengths. The apparatus may include a series of reflective and/or refractive apparatuses to alter the reflection path of the emitted electromagnetic radiation, allowing the electromagnetic radiation to reflect in a plurality of directions. The enclosure may include a support member or personal item support that may be transparent to, or reflective of, the electromagnetic radiation.

Abstract: An innovative equipment system comprises a tap water reservoir system, a disinfectant reactor system, a pump system, a disinfection and safety door spraying system, a sewage recycling system and a sewage treatment system, wherein the tap water reservoir system is mainly configured to store tap water in advance according to actual cargo volumes and disinfection requirements, and generally in tons; and the disinfectant reactor system comprises boron-doped diamond electrode modules, a reactor indicating lamp module, a visible reactor, a smart control screen, at least one water tank and a structure protection module. The Innovative disinfection and sterilization equipment system can easily kill bacteria and viruses such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, and new coronavirus in a short time and enhance disinfection efficiency.

Abstract: A sterilization and deodorization waste container having dual-wave band ultraviolet lamp tube includes an isolation chamber provided on an inner side of a container lid and a dual-wave band ultraviolet lamp tube installed in the isolation chamber. The dual-wave band ultraviolet lamp tube is capable of simultaneously generating a direct ultraviolet light wave and an ozone ultraviolet light wave. The isolation chamber includes a reflector housing having a light transmitting window facing an inner cavity of a container body. The dual-wave band ultraviolet lamp tube is controlled by a control circuit to turn on to generate the ultraviolets into an inner cavity of the container body while the container lid is closed and to turn off to stop generating the ultraviolet while the container lid is opened.

Abstract: A work type identification apparatus (2000) acquires, for a target region (12) of a target object (10) on which a wiping work is to be performed, a temperature data sequence (40) indicating a time variation of a temperature of the target region (12). The work type identification apparatus (2000) determines a type of wiping work performed on the target region (12) based on the time variation of the temperature of the target region (12) indicated by the temperature data sequence (40).

Abstract: Systems and methods provide hand hygiene compliance data at an intelligent hand hygiene device. The system detects that a user is in proximity to the hand hygiene device, then matches the user to one or more user profiles within the system. The system then detects that at least one hand of the user has been placed under a dispensing component of the hand hygiene device, and instructs the dispensing component to dispense hand sanitizer. The system collects compliance data for the user corresponding to hand hygiene compliance, then associates the compliance data for the user with the one or more user profiles corresponding to the user. The system then determines or updates a compliance rate of the user based on the compliance data associated with the user, and transmits the compliance rate of the user to at least one client device associated with a designated user.

Abstract: The invention provides a reversibly protected colorant or a composition thereof which when mixed with a disinfectant solution imparts color to the disinfectant solution allowing for temporary visualization of a disinfectant, and methods for use in the disinfection, decontamination, and/or cleaning of surfaces, objects. The reversibly protected colorant or composition thereof is added to a disinfectant solution or disinfectant article (e.g., disinfectant wipe, microfiber, rag, towel, cloth, spun-woven wipes, nonwoven wipes, etc.), wherein the reversibly protected colorant or a composition thereof imparts color to the disinfectant solution resulting in a colored disinfectant solution until such protection is removed, thereby releasing the colorant and exposing the colorant to an agent and/or oxidizing conditions that cause the colorant to permanently lose its color.

Abstract: The present invention relates to a composition comprising a) at least 10 wt. % of at least one C1 to C4 monohydric alcohol; b) at least 20 wt.% of at least one solvent selected from the group consisting of solketal, acetone, methylpropyl ketone, dipropyl ketone, dimethyl sulfoxide, glycerine carbonate, propylene carbonate, butylene carbonate, glycerine formal, 2-ethyl hexanol, 2-butyl octanol, 2- hexyl decanol, 2-octyl dodecanol, and mixtures thereof; c) between 0.001 wt. % and 5 wt. % of at least one active constituent selected from the group consisting of fragrances, air-sanitisers, deodorizers, odor eliminators, malodor counteractants, insecticides, insect repellents, medicinal substances, disinfectants, aroma therapy compositions and combinations thereof; and d) water. The invention further relates to a device comprising a container and a dispenser, wherein the container contains the composition according to the invention.

Abstract: A solid article for sustained delivery of volatile materials in an interior space that is subject to temperature fluctuations of at least 5° C. Such solid article comprises one or more non-aqueous volatile materials in a chemically cross-linked gel. The chemically cross-linked gel is formed by mixing one or more polyols or derivatives thereof with a cross-linking agent at a weight ratio of from 1:0.1 to 1:0.8, and the solid article is characterized by a thermal conductivity of from 0.16 W/mK to 0.2 W/mK.

Abstract: A wearable protective device includes headwear having a brim and a germicidal light source attached to the brim. An optical reflective channel is designed to direct light generated by the germicidal light source away from the headwear and downward to illuminate area in front of a wearer's face. The headwear may be virtually any type of brimmed head garment. The germicidal light source is preferably an ultraviolet light source that generates UV-C light radiation to destroy airborne pathogens, including bacteria and viruses.

Abstract: Described are fiber materials with improved properties and a process for producing the same. The fiber materials have, at the same time, improved mechanical and antimicrobial properties as well as improved wear properties (i.e. “softness”), without the occurrence of severe discoloration imparted by the antimicrobial agent added.

Abstract: A kaolin-based hemostatic gauze comprises: a medical non-woven fabric as a carrier; and a kaolin-containing composite hemostatic material loaded on the medical non-woven fabric, wherein kaolin serves as a carrier in the kaolin-containing composite hemostatic material, the kaolin is doped with Ce and ?-Fe2O3 is loaded on the Kaolin. A method for preparing the kaolin-based hemostatic gauze, includes: S1: preparing the kaolin-containing composite hemostatic material; S2: preparing the kaolin-containing composite hemostatic material into a suspension; S3: impregnating the medical non-woven fabric with the suspension thoroughly stirred, wherein upper and lower sides of the medical non-woven fabric each are impregnated once; and S4: pressing and oven-drying an impregnated medical non-woven fabric to obtain the kaolin-based hemostatic gauze.

Abstract: A composition of matter useful as a bioadhesive including a bistable adhesive polymer. The bistable adhesive polymer includes one or more polymer backbones; side-chains attached to each of the polymer backbones; and one or more transition temperatures between a crystalline state and an amorphous state. The one or more transition temperatures are such that the polymer transitions from the crystalline state to the amorphous state upon physical contact with biological tissue having a temperature higher than the transition temperature. The polymer adheres or attaches to the biological tissue in the amorphous state and can be peeled from the biological tissue when cooled below the transition temperature to the crystalline state.

Abstract: A porous implant design method includes defining a design volume for a porous implant, a load to be borne by the design volume, and an objective function solution characteristic related to the design volume. Next, the load is divided into a plurality of sub-loads and an optimization procedure is performed: until all sub-loads have been applied, one of the plurality of sub-loads is applied to the material in the design volume, material from the design volume is removed such that remaining material within the design volume is capable of bearing one of the plurality of sub-loads while satisfying the objection function solution characteristic; the remaining material defines a void space without material, the void space is set as a new design volume for any remaining sub-loads, the new design volume is set as being full of material. Then, the remaining material from each cycle of the optimization is combined.

Abstract: Described herein are methods to increase growth factor binding when demineralizing bone. Also described herein are methods of enriching bound growth factors in a medical implant.